Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416924 | 1.00 | ALDH1A1 (0.35) | ALDH1A1DGAT1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL421215 | 1.00 | ALDH1A1 (0.35) | ALDH1A1DGAT1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7560867 | 0.96 | ALDH1A1 (0.37) | ALDH1A1DGAT1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12658242 | 0.93 | DGAT1 (0.34) | ALDH1A1DGAT1 | |
| SCHEMBL9136368 | 0.93 | DGAT1 (0.34) | ALDH1A1DGAT1 | |
| SCHEMBL11938228 | 0.91 | DGAT1 (0.36) | ALDH1A1DGAT1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7559948 | 0.87 | ALDH1A1 (0.32) | ALDH1A1DGAT1 | |
| SCHEMBL8956185 | 0.87 | ALDH1A1 (0.32) | ALDH1A1DGAT1 | |
| SCHEMBL6017763 | 0.86 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL418256 | 0.86 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133905-A1 | CURABLE COMPOSITION, CURED FILM, METHOD OF PRODUCING CURED FILM, ELEMENT, AND DISPLAY DEVICE | AGC Inc. (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-3144297-A1 | ETHEREAL OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR PRODUCING SAME | Asahi Glass Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170050934-A1 | ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION | ASAHI GLASS COMPANY, LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3093284-A1 | ETHEREAL OXYGEN-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | Asahi Glass Company, Limited (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-20160295864-A1 | ETHEREAL OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE RING COMPOUND AND METHOD FOR ITS PRODUCTION | ASAHI GLASS COMPANY, LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| EP-0965335-B1 | Metered-dose aerosol formulations | MINNESOTA MINING & MFG (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-0965335-A1 | Metered-dose aerosol formulations | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0636362-B1 | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations | MINNESOTA MINING & MFG (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0526481-B1 | THE USE OF SOLUBLE FLUOROSURFACTANTS FOR THE PREPARATION OF METERED-DOSE AEROSOL FORMULATIONS | MINNESOTA MINING & MFG (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5399718-A | Direct fluorination process for making perfluorinated organic substances | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0636362-A2 | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5362919-A | Direct fluorination process for making perfluorinated organic substances | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0609200-A1 | DIRECT FLUORINATION PROCESS FOR MAKING PERFLUORINATED ORGANIC SUBSTANCES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1990006296-A1 | DIRECT FLUORINATION PROCESS FOR MAKING PERFLUORINATED ORGANIC SUBSTANCES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160295864-A1 | ETHEREAL OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRAZOLE RING COMPOUND AND METHOD FOR ITS PRODUCTION | CYP2F1, CYP2E1, CYP2C19 | ALDH1A1 738/4885DGAT1 615/4885CYP1A2 5/4885 |
| US-20170050934-A1 | ETHERIC (ETHEREAL) OXYGEN ATOM-CONTAINING PERFLUOROALKYL GROUP-SUBSTITUTED PYRIMIDINE RING COMPOUND, AND METHOD FOR ITS PRODUCTION | CYP2B6, PFAS, CYP2F1 | ALDH1A1 1430/4885DGAT1 789/4885CYP1A2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.